%0 Journal Article
%T Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.
%A Kim J
%A Gianferante M
%A Karyadi DM
%A Hartley SW
%A Frone MN
%A Luo W
%A Robison LL
%A Armstrong GT
%A Bhatia S
%A Dean M
%A Yeager M
%A Zhu B
%A Song L
%A Sampson JN
%A Yasui Y
%A Leisenring WM
%A Brodie SA
%A de Andrade KC
%A Fortes FP
%A Goldstein AM
%A Khincha PP
%A Machiela MJ
%A McMaster ML
%A Nickerson ML
%A Oba L
%A Pemov A
%A Pinheiro M
%A Rotunno M
%A Santiago K
%A Wegman-Ostrosky T
%A Diver WR
%A Teras L
%A Freedman ND
%A Hicks BD
%A Zhu B
%A Wang M
%A Jones K
%A Hutchinson AA
%A Dagnall C
%A Savage SA
%A Tucker MA
%A Chanock SJ
%A Morton LM
%A Stewart DR
%A Mirabello L
%J JNCI Cancer Spectr
%V 5
%N 2
%D 04 2021
%M 34308104
暂无%R 10.1093/jncics/pkab007
%X Pediatric cancers are the leading cause of death by disease in children despite improved survival rates overall. The contribution of germline genetic susceptibility to pediatric cancer survivors has not been extensively characterized. We assessed the frequency of pathogenic or likely pathogenic (P/LP) variants in 5451 long-term pediatric cancer survivors from the Childhood Cancer Survivor Study.<BR>Exome sequencing was conducted on germline DNA from 5451 pediatric cancer survivors (cases who survived ≥5 years from diagnosis; n = 5105 European) and 597 European cancer-free adults (controls). Analyses focused on comparing the frequency of rare P/LP variants in 237 cancer-susceptibility genes and a subset of 60 autosomal dominant high-to-moderate penetrance genes, for both case-case and case-control comparisons.<BR>Of European cases, 4.1% harbored a P/LP variant in high-to-moderate penetrance autosomal dominant genes compared with 1.3% in controls (2-sided P = 3 × 10-4). The highest frequency of P/LP variants was in genes typically associated with adult onset rather than pediatric cancers, including BRCA1/2, FH, PALB2, PMS2, and CDKN2A. A statistically significant excess of P/LP variants, after correction for multiple tests, was detected in patients with central nervous system cancers (NF1, SUFU, TSC1, PTCH2), Wilms tumor (WT1, REST), non-Hodgkin lymphoma (PMS2), and soft tissue sarcomas (SDHB, DICER1, TP53, ERCC4, FGFR3) compared with other pediatric cancers.<BR>In long-term pediatric cancer survivors, we identified P/LP variants in cancer-susceptibility genes not previously associated with pediatric cancer as well as confirmed known associations. Further characterization of variants in these genes in pediatric cancer will be important to provide optimal genetic counseling for patients and their families.